Compare WWR & MYO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WWR | MYO |
|---|---|---|
| Founded | 1977 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Industrial Specialties |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.4M | 63.8M |
| IPO Year | 2006 | 2017 |
| Metric | WWR | MYO |
|---|---|---|
| Price | $0.42 | $1.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $2.17 | ★ $4.64 |
| AVG Volume (30 Days) | ★ 683.7K | 238.3K |
| Earning Date | 11-11-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,000,000,000.00 |
| Revenue This Year | N/A | $11.43 |
| Revenue Next Year | N/A | $12.29 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 40814.79 |
| 52 Week Low | $0.38 | $0.61 |
| 52 Week High | $1.51 | $1.89 |
| Indicator | WWR | MYO |
|---|---|---|
| Relative Strength Index (RSI) | 37.85 | 46.90 |
| Support Level | $0.39 | $1.18 |
| Resistance Level | $0.45 | $1.75 |
| Average True Range (ATR) | 0.02 | 0.10 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 45.04 | 48.28 |
Westwater Resources Inc is an energy technology company focused on developing battery-grade natural graphite materials through a vertically integrated, mine-to-market strategy anchored by its two primary projects in Coosa County, Alabama: the Kellyton Graphite Plant and the Coosa Graphite Deposit. Westwater also holds mineral rights to explore and mine the Coosa Graphite Deposit, which Westwater anticipates will eventually provide natural graphite flake concentrate as feedstock to the Kellyton Graphite Plant.
Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA). Geographically, it derives maximum revenue from the United States, followed by Germany, and other international.